Obamacare Health Plans Increase HIV Viral Suppression Rates Better Than Ryan White Drug Coverage
Giving health coverage to people with HIV seems to increase viral suppression. But the future of health coverage gains in the U.S. is uncertain.
This Week in HIV Research: U=U Grows Ever Stronger
Oct. 10, 2019: Long-term viral suppression = zero genital tract shedding among women; HIV treatment initiation and sexual risk among MSM; PrEP interest vs. uptake among trans women of color; polypharmacy among people living with HIV.
The HIV Workforce Is in Trouble. Here Are Three Solutions to Address the Shortage of Providers.
If everyone living with HIV gets into care, do we have enough providers to support them? HIV doctors are proposing policy changes to address the workforce shortage.
Test-and-Treat for Hepatitis C: What Are the Obstacles?
A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.
Our Newest Posts
Two-Drug Regimen Is Being Studied as a Long-Acting Injectable. But Does It Work as a Daily Pill?
New analysis of the LATTE trial shows the two drugs cabotegravir and rilpivirine may also work as a daily oral formulation, which could be a bridge therapy for people who miss an injectable appointment.
Best Practices for Most Vulnerable Populations: Transgender People, Adolescents, and the Recently Incarcerated
"As we think about the care cascade, we can't even test people [for HIV] to diagnose them if we can't get them in the door to a health care setting," one clinician said.
This Week in HIV Research: Much Ado About Lipids
Oct. 17, 2019: Tesamorelin as treatment for non-alcoholic fatty liver disease; reversing lipid changes via TDF => TAF => TDF; statin use and reduced chronic kidney disease risk; statin use and (no) reduced HIV persistence.
Two-Drug HIV Regimen Works Well Except in People With Low CD4 Count, Study Finds
The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.
Gilead Announced It Will Donate 2.4 Million Bottles of Truvada for PrEP. Here's How It Will Work.
Gilead Sciences is working with the federal government to roll out its pre-exposure prophylaxis (PrEP) donation program. Here, we detail what we know so far about how this will be implemented.
Getting Hepatitis C Treatment to People in Jails Isn’t Easy. Here Are Some Recommendations.
People in jail, who are often in the system for less time than those in prison, often receive little to no hepatitis C screening or treatment. One provider works to change this in Massachusetts.
Refer your clients and patients to TheBody, TheBodyPro's sibling site for people living with or affected by HIV. TheBody delivers vital information, news, support, and personal perspectives on HIV and related issues.
